Eversept Partners LP grew its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by 147.2% during the fourth quarter, Holdings Channel reports. The firm owned 718,582 shares of the company’s stock after purchasing an additional 427,909 shares during the period. Eversept Partners LP’s holdings in Maravai LifeSciences were worth $2,335,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. AQR Capital Management LLC raised its holdings in shares of Maravai LifeSciences by 80.5% during the 4th quarter. AQR Capital Management LLC now owns 111,131 shares of the company’s stock valued at $361,000 after purchasing an additional 49,551 shares in the last quarter. Jain Global LLC bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at $36,000. Russell Investments Group Ltd. raised its holdings in shares of Maravai LifeSciences by 18.2% during the 4th quarter. Russell Investments Group Ltd. now owns 132,741 shares of the company’s stock valued at $431,000 after purchasing an additional 20,434 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at $133,000. Finally, Yost Capital Management LP bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at $410,000. Institutional investors own 50.25% of the company’s stock.
Insider Activity
In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.
Maravai LifeSciences Stock Performance
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. As a group, analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.
Wall Street Analysts Forecast Growth
MRVI has been the topic of several recent analyst reports. Wells Fargo & Company lifted their target price on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a report on Friday, May 8th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of “Hold” and an average target price of $5.50.
Get Our Latest Stock Report on Maravai LifeSciences
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Read More
- Five stocks we like better than Maravai LifeSciences
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
